FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder
Published
Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura…
#adzynma #ert #fda #petermarks #phd #cttp #adamts13 #adyznma #ttp #reviewvoucher